A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like What is dihexa, its mechanism of action via the HGF c Met pathway, and its safety and clinical use? DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica